Focus: Surge is an early-stage oncology biotech using machine learning to decode immune system signals from blood samples for patient outcome prediction. The company is pre-revenue with a nascent pipeline focused on solid tumors.
Profile data last refreshed 5h ago · AI intelligence enriched 4mo ago
Hot — 550 jobs added in 30d
Net +35 (550 new, 515 removed). Aggressive expansion phase.
Surge is a speculative, science-heavy opportunity suitable only for risk-tolerant early-career or senior scientists betting on AI-driven immunology; hiring is minimal and financial viability is opaque.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Surge
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Surge's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles